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BACKGROUND: The compound 3,4-methylenedioxymethamphetamine (MDMA) is a potent monoamine releaser
that produces an acute euphoria in most individuals.
METHODS: In a double-blind, placebo-controlled, balanced-order study, MDMA was orally administered to 25
physically and mentally healthy individuals. Arterial spin labeling and seed-based resting state functional connectivity
(RSFC) were used to produce spatial maps displaying changes in cerebral blood flow (CBF) and RSFC after MDMA
administration. Participants underwent two arterial spin labeling and two blood oxygen level–dependent scans in a
90-minute scan session; MDMA and placebo study days were separated by 1 week.
RESULTS: Marked increases in positive mood were produced by MDMA. Decreased CBF only was observed after
MDMA, and this was localized to the right medial temporal lobe (MTL), thalamus, inferior visual cortex, and the
somatosensory cortex. Decreased CBF in the right amygdala and hippocampus correlated with ratings of the
intensity of global subjective effects of MDMA. The RSFC results complemented the CBF results, with decreases in
RSFC between midline cortical regions, the medial prefrontal cortex, and MTL regions, and increases between the
amygdala and hippocampus. There were trend-level correlations between these effects and ratings of intense and
positive subjective effects.
CONCLUSIONS: The MTLs appear to be specifically implicated in the mechanism of action of MDMA, but further
work is required to elucidate how the drug’s characteristic subjective effects arise from its modulation of
spontaneous brain activity.
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Biohttp://dx.doi.org/10.1016/j.biopsych.2013.12.015The compound 3,4-methylenedioxymethamphetamine (MDMA)
releases serotonin (5-hydroxytryptamine [5-HT]), dopamine,
and norepinephrine (1). It is also a popular recreational drug
that is valued by users because of its acute prosocial and
euphoretic properties (2). Although MDMA has been adminis-
tered in human research on numerous occasions (3–5), few
studies have investigated its acute effects on brain function
using functional magnetic resonance imaging (fMRI) (6–8) or
other neuroimaging modalities (9–11).
The compound MDMA has a relatively unique profile of
subjective effects, described as a hybrid between a stimulant4 & 2015 The Authors. Published by Elsevier Inc. on behalf of Socie
logical Psychiatry October 15, 2015; 78:554–562 www.sobp.org/journ
SEE COMMENTARYand psychedelic (12). It acts at dopamine, norepinephrine, and
5-HT transporters to inhibit reuptake and stimulate release;
however, the greater action of MDMA at the serotonin trans-
porter differentiates it from most other stimulants (13) and
accounts for much, but not all, of its euphoretic effects (14,15).
Although the pharmacology of MDMA is reasonably well
understood, little is known about its effects on global brain
function. More recently, MDMA has been investigated as
a potential adjunct to psychotherapy in the treatment of
posttraumatic stress disorder (PTSD), with positive, albeit
preliminary, outcomes (16,17).ty of Biological Psychiatry. All rights reserved.
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The Effects of Acutely Administered
Biological
PsychiatryDespite significant developments in resting state fMRI in
recent years (18), there have been no resting state fMRI studies
on the acute effects of MDMA. In the present study, we
combined arterial spin labeling (ASL) and resting state functional
connectivity (RSFC) to address this knowledge gap. The mag-
netic resonance imaging technique ASL provides a quantitative
measure of cerebral blood flow (CBF) or perfusion (19), and
RSFC measures functional coupling between spatially distributed
brain regions via spontaneous fluctuations in the blood oxygen
level–dependent (BOLD) signal (20). Combining these comple-
mentary techniques can yield important new information on how
a drug alters brain activity to produce its characteristic subjective
effects (21). Given the recognized acute prosocial and positive
mood effects of MDMA (6,22), we predicted changes in CBF and
RSFC in brain systems implicated in social and affective
processing—limbic structures and the medial prefrontal cortex
(mPFC) (23,24). On this basis, three regions (i.e., ventromedial
prefrontal cortex [vmPFC], bilateral hippocampi, and amygdalae)
were selected for seed-based RSFC analyses (20).
Supporting the importance of this research is: 1) the relative
dearth of human functional neuroimaging data on what is one
of the most popular drugs of potential misuse (25); 2) the
ability of MDMA to produce an acute state of euphoria and the
poor understanding of the neural underpinnings of such states
(26); 3) the ability of MDMA to produce marked 5-HT release
(13), supporting its utility in serotoninergic challenge (27);
and 4) preliminary evidence for the potential of MDMA as a
therapeutic agent (17).
METHODS AND MATERIALS
Supplement 1 contains the complete Methods and Materials
section.
Design
This was a within-subjects, double-blind, randomized, placebo-
controlled study. Participants were scanned twice, 7 days apart
—once after MDMA and once after placebo. A schematic of the
scanning protocol is shown in Figure 1. The study was approved
by the National Research Ethics Service West London Research
Ethics Committee, Joint Compliance and Research Office of
Imperial College London, Research Ethics Committee of Imperial
College London, Head of the Department of Medicine of Imperial
College London, Imanova Centre for Imaging Science, and
Faculty of Medicine of Imperial College London. The study was
conducted in accordance with Good Clinical Practice guidelines.
A Home Office Licence was obtained for the storage and
handling of a Schedule 1 drug. Imperial College London
sponsored the research.Biological PsycParticipants
The study included 25 healthy participants (mean age, 34 6 11
years; 7 females) with at least one previous experience with
MDMA. None of the participants had used MDMA for at least
7 days or other drugs for at least 48 hours, which was confirmed
by a urine screen. An alcohol breathalyzer test confirmed that
none of the participants had recently consumed alcohol. Partic-
ipants had used MDMA an average of 35 6 51 times before
(range, 1–200 times), and the mean time since last use was 1400
6 2351 days (range, 7–7300 days). Participants were screened
for good physical and mental health, and magnetic resonance
imaging compatibility. Screening involved routine blood tests,
electrocardiogram, heart rate, blood pressure, and a brief neuro-
logic examination. The Mini International Neuropsychiatric Inter-
view version 5 (MINI-5) was performed by an experienced
psychiatrist to assess mental health. All subjects were deemed
physically and mentally healthy, and none had any history of
drug or alcohol dependence or diagnosed psychiatric disorder.
Participants had mean Beck Depression Inventory scores of
3.9 6 4.8 (range, 0–18) and Spielberger State-Trait Anxiety
Inventory scores of 31.7 6 5.9 (range, 20–46).
RESULTS
Basic Subjective and Physiologic Effects
The intensity of the subjective effects of MDMA was variable
across subjects. Five subjects failed to notice any subjective
effects during the scanning period, whereas three gave
maximal ratings, indicating “extremely intense” effects. Peak
drug effects were reported 100 min after ingestion of MDMA
(the intensity was rated at 52 6 32%; range, 0%–100%; 0% 5
no effects and 100% 5 extremely intense effects) coinciding
with the beginning of the second ASL scan (103 min after
capsule ingestion). However, the average intensity remained
relatively consistent throughout the scanning period (i.e.,
intensity was rated at 44 6 35% at the end of the first ASL
scan and 43 6 32% at the end of the second BOLD scan).
Most volunteers reported positive mood effects after MDMA,
and items referring to aspects of positive mood were among
the highest scored (e.g., the item “I felt amazing” was the
highest rated item after MDMA administration) (Figure 2).
Mean Plasma Concentration of MDMA
Biochip Array Technology (Randox Laboratories Ltd., Co.,
Antrim, United Kingdom) was used to detect MDMA from
plasma samples obtained shortly after each participant’s
MDMA scanning session (i.e., 2 hours after capsule ingestion).
The mean concentration of MDMA was 214 6 66 ng/mL.Figure 1. Schematic showing scanning protocol.
Placebo (vitamin C) or 3,4-methylenedioxymetham-
phetamine (MDMA) hydrochloride (100 mg) was
ingested at time zero, and the first arterial spin
labeling scan performed 50 min later. This was a
repeated measures design; the two scans (placebo
and MDMA) were performed 1 week apart, and the
scan order was counterbalanced so that half of the
volunteers received MDMA for the first scan, and half
received MDMA for the second scan. ASL, arterial
spin labeling; BOLD, blood oxygen level–dependent.
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Figure 2. Subjective effects of 3,4-methylenediox-
ymethamphetamine (MDMA). There were 29 items
rated 4 hours after drug administration. Participants
were instructed to complete the items with reference
to the peak drug effects (where applicable). The items
marked with an asterisk were rated significantly
higher after MDMA than placebo (p , .001, Bonfer-
roni correction for multiple comparisons). The mean
ratings for 25 participants are shown plus the positive
standard errors from the mean (SE).
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Subtracting the two ASL scans after MDMA administration
from the two ASL scans after placebo revealed robust
decreases in CBF after MDMA. The images shown in
Figure 3A were produced using cluster-correction (2590
voxels) to adjust for multiple comparisons and a whole-brain
corrected statistical threshold of p , .05. At this threshold,
decreases in CBF only were observed, and these were556 Biological Psychiatry October 15, 2015; 78:554–562 www.sobp.olocalized to the regions shown in Figure 3A. Increases in
CBF could be observed only at an unacceptable statistical
threshold of puncorrected , .3. For a more comprehensive
display of the regional decreases in CBF after MDMA, see
Supplement 1.
When contrasts were split so that the effect of MDMA in the
first and second ASL scans could be observed separately,
consistent maps were revealed, with decreases in CBF only
after MDMA. The decreases were slightly more marked and ofFigure 3. Decreases in cerebral blood flow (CBF)
after administration of 3,4-methylenedioxymetham-
phetamine (MDMA). (A) Regions of significantly less
CBF after MDMA administration (scans 1 and 2) vs.
placebo (scans 1 and 2) are displayed. These images
are cluster-corrected giving a whole-brain corrected
statistical threshold of p , .05. See Supplement 1 for
additional slices. (B,C) Decreased right amygdala and
hippocampal CBF predicts intense subjective effects
after MDMA. Values on the x-axis are ratings from the
first and second arterial spin labeling scans after
MDMA administration. A corrected p value of
, .005 was used. The decreases in CBF after MDMA
administration versus placebo increase in magnitude
from left to right. The greater the decreases in CBF in
the amygdalae and hippocampi after MDMA admin-
istration, the more intense were the drug’s subjective
effects. ASL, arterial spin labeling; hipp, hippo-
campus.
rg/journal
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(Supplement 1).
Correlations between CBF Effects and Subjective
Ratings
Regions showing the most marked reductions in CBF after
MDMA administration included the visual cortex, thalamus,
somatosensory cortex, right hippocampus, and right amyg-
dala. Correlational analyses were restricted to these regions of
interest. Masks were derived from an anatomic atlas, and CBF
changes in the relevant regions were correlated with self-
ratings of the intensity of the subjective effects of MDMA.
Significant positive correlations were observed between the
magnitude of the CBF decreases in the right amygdala (p 5
.002) and right hippocampus (p 5 .004) after MDMA admin-
istration and the subjective intensity of the drug effects
(Figure 3B,C). Correcting for multiple comparisons gave a
revised statistical threshold of p , .005 (.05/10), and these
correlations survived this threshold. Because the amygdala
and hippocampus are limbic structures known to be involved
in affective processing, we also examined correlations
between the CBF changes and ratings of increased positive
affect after MDMA administration, and although correlations
were in the predicted direction, no significant relationships
were found.
RSFC Results
When vmPFC RSFC after MDMA administration was con-
trasted against vmPFC RSFC after placebo administration,
significant increases (yellow-orange color) and decreases (blue
color) were observed (cluster-corrected, z 5 2.3, p , .05; this
threshold was used for all of the RSFC analyses). Increases in
vmPFC RSFC were observed in visual cortex, both medially
and laterally (left and right hemispheres). Decreases were
found in the midbrain (including voxels in the vicinity of the
dorsal raphe nuclei), thalamus, amygdala, and posterior cin-
gulate cortex (PCC).
When hippocampal RSFC after MDMA administration was
contrasted against hippocampal RSFC after placebo admin-
istration, significant increases in RSFC were observed in the
dorsal ACC, right amygdala, and right middle frontal gyrus.
Decreases were found in the mPFC, left posterior parahippo-
campal/fusiform gyrus, and left temporal cortex.
When amygdala RSFC after MDMA administration was
contrasted against amygdala RSFC after placebo administra-
tion, significant increases in RSFC were observed in the
brainstem and bilaterally in the anterior parahippocampal
gyrus. Decreases in RSFC were found in the cerebellum, left
temporal cortex, medial orbitofrontal cortex, and subgenual
cingulate cortex. For images of positive RSFC to the regions of
interest during baseline conditions, see Supplement 1.
Relationship between Changes in RSFC and
Subjective Effects of MDMA
Six correlations were tested, giving a revised statistical thresh-
old of p , .008 (.05/6). Specifically, between-condition differ-
ences in vmPFC-PCC, hippocampal-vmPFC, and amygdala-
hippocampal RSFC versus ratings of the intensity of the globalBiological Psycsubjective effects of MDMA and ratings of positive mood were
tested. There was a trend toward decreased vmPFC-PCC
RSFC after MDMA administration correlating with intense
(r 5 .13, p 5 .218) and positive (r 5 .36, p 5 .038) subjective
effects, but neither correlation was significant. Similarly, there
was a trend toward decreased hippocampal-vmPFC RSFC
after MDMA administration correlating with intense (r 5 .32,
p 5 .026) and positive (r 5 .3, p 5 .073) effects, but neither
correlation was significant. Finally, there was a trend toward
increased amygdala-hippocampal RSFC correlating with
intense (r 5 .382, p 5 .01) and positive (r 5 .159, p 5 .225)
subjective effects, but these correlations were not significant
when corrected for multiple testing.
Addressing Between-Condition Differences in
Motion as a Potential Confounder
All available methods were employed to control for subjective
motion in the RSFC analyses (e.g., motion parameter time
courses and outlier volumes were included as confounder
variables in the first-level general linear models). In addition,
between-condition motion in the resting state BOLD scans
was formally compared. There was significantly more move-
ment in the MDMA than placebo scans (p 5 .003); however,
the magnitude of this difference was so small as to be
functionally insignificant (i.e., the mean relative movement
per volume in the RSFC scans was .072 6 .04 mm after
placebo administration and 0.099 6 .08 mm after MDMA
administration. Mean motion failed to explain any of the
variance in the main RSFC outcomes when tested in post
hoc regression analyses containing the between-condition
differences in RSFC as the dependent variable and between-
condition differences in motion as a single explanatory
variable.
Addressing Between-Subject Differences in Drug
Use as a Potential Confounder
Because there was a large variability in previous drug use
among the study sample, additional regression analyses were
run to test for relationships between drug use and between-
condition differences in RSFC. Specifically, using the same
approach outlined previously, between-condition differences
in RSFC were entered as the dependent variable, and previous
MDMA exposure, recency of MDMA exposure, weekly alcohol
use, and lifetime cannabis use were entered separately as
single explanatory variables. Between-subject variance in drug
use failed to explain significantly any of the between-condition
RSFC outcomes.DISCUSSION
This is the first resting state fMRI study on the acute effects of
MDMA on spontaneous brain function. Decreased CBF was
seen in the amygdala and hippocampus, and this correlated
with the intensity of the drug’s effects. Decreases in vmPFC-
MTL and vmPFC-PCC RSFC and increase in amygdala-
hippocampal RSFC were also observed, and there were
trend-level correlations between these effects and the intensity
and positive mood effects of MDMA.hiatry October 15, 2015; 78:554–562 www.sobp.org/journal 557
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subcalcarine visual cortex, pre–supplementary motor area,
somatosensory cortex, superior frontal gyrus, midbrain and
brainstem, thalamus, hippocampus and parahippocampus,
and amygdala. The 5-HT1B receptor is especially densely
expressed in the subcalcarine domain of the visual cortex
(28), which is precisely where the CBF decreases in the visual
cortex were observed. It is natural to infer that endogenous
5-HT released by MDMA may have stimulated this particular
5-HT receptor in this particular region to produce the observed
decreases in CBF. Supporting the role of 5-HT in mediating
this and the other main effects, MDMA produces a 5-fold
greater increase in synaptic 5-HT than dopamine (13), and
dopamine and norepinephrine receptors are not densely
expressed in the visual cortex.
The decreases in CBF in the MTLs were one of the most
intriguing results of this study, particularly because the magni-
tude of these decreases correlated positively with ratings of the
drug’s global subjective effects, even after correcting for multiple
comparisons (Figure 3B,C). The MTL structures receive an
especially dense serotoninergic innervation (29), and 5-HT is
found in higher concentrations in the hippocampus than dop-
amine and norepinephrine (30). The hippocampus (31) and
amygdala (32) express postsynaptic 5-HT1A receptors in high
concentrations, endogenous 5-HT has a relatively high affinity for
5-HT1A receptors (27), and the effects of 5-HT stimulation of
5-HT1A receptors are hyperpolarization and a decrease in cell
firing rate (33). Other 5-HT receptors are expressed in the
hippocampus, amygdala, and parahippocampus (e.g., the
5-HT7 receptor and 5-HT2A receptor (34,35)) but to a far lesser
extent than the 5-HT1A receptor (36). It is reasonable to infer that
the marked decreases in CBF in the MTLs were caused by an
effect of 5-HT on inhibitory postsynaptic 5-HT1A receptors.
Elevated limbic activity is a reliable characteristic of anxiety
states (37). Serotoninergic medications with anxiolytic proper-
ties, such as selective serotonin reuptake inhibitors and
5-HT1A receptor agonist buspirone, are thought to elicit their
therapeutic action via stimulation of inhibitory postsynaptic
5-HT1A receptors, normalizing limbic activity (38). Acutely
administered MDMA does not appear to have typical anxiolytic
properties in either animals or humans (17,39); however, the
subjective ratings displayed in Figure 2 clearly demonstrate an
increase in positive mood under the influence of the drug
(albeit without any effect on negative mood—which was
already low). Prosocial behaviors have previously been
observed after MDMA administration (2,22,40), and MDMA-
induced prosocial behavior in rats was reduced after pretreat-
ment with a selective 5-HT1A receptor antagonist (41). Given
the potent serotonin releasing properties of MDMA (1,13), it
can be inferred that the reduced MTL CBF observed here was
mediated by 5-HT1A receptor stimulation and is related, at
least in part, to the drug’s positive mood effects. However,
contradicting the role of 5-HT1A receptors in the mechanism of
action of MDMA is the finding that pretreatment with pindolol
does not significantly attenuate the drug’s subjective effects
(14,42); pindolol is a partial agonist that may not provide
effective blockade of postsynaptic 5-HT1A receptors (43,44).
Pretreatment studies with potent and selective antagonists are
required to elucidate the specific receptor subtypes mediating
the decreases in CBF.558 Biological Psychiatry October 15, 2015; 78:554–562 www.sobp.oSimilar to the ASL outcomes, the RSFC analyses also
yielded robust results. For example, the decreases in
vmPFC-PCC coupling after MDMA administration are of
interest given more recent evidence that increased vmPFC-
PCC coupling is positively associated with rumination in
depression (45). On this basis, we had predicted that the
decreases in vmPFC-PCC RSFC would correlate with the
drug’s positive mood effects, but although there was a trend in
this direction, it was not significant after correction or multiple
comparisons. Decreased vmPFC-PCC RSFC has also been
found with psilocybin (21), a nonselective 5-HT2A receptor
agonist with potent consciousness-altering properties. Psilo-
cybin produces an unconstrained style of cognition that is the
inverse of the constrained, ruminative style of thinking that is
characteristic of depression. Participants described a similar
liberation of cognition and imagination after MDMA adminis-
tration (Figure 2), and vmPFC-PCC coupling was decreased
after administration of the drug. In future research with MDMA,
it would be interesting to incorporate pretreatment with a
selective 5-HT2A receptor antagonist to test the involvement of
this specific receptor in mediating the drug’s effects. The
5-HT2A receptor is highly expressed in both the mPFC and
PCC (46), and 5-HT2A receptor blockade was found to
significantly attenuate the positive mood effects of both
MDMA (14) and psilocybin (47).
Regarding other circuitry implicated in the action of MDMA,
decreased mPFC-hippocampal RSFC was observed
(Figure 4). The uncinate fasciculus connects the vmPFC and
MTL structures (48), and other indirect connections (e.g., via
the retrosplenial cortex and ventral PCC) likely account for the
substantial baseline functional connectivity seen between
these regions (Supplement 1). Research in rodents has shown
that the mPFC exerts a top-down inhibitory influence on limbic
activity (49), often observed in the context of emotional control
(50). These regions have also been implicated in the patho-
physiology of PTSD. For example, patients with pronounced
dissociative symptoms exhibit elevated mPFC and reduced
MTL responses to trauma-related cues (51) presumably as a
result of an exaggerated influence of the mPFC on the MTLs
(52). More recently, MDMA has begun to be formally inves-
tigated as an adjunct to psychotherapy for PTSD (16,17). It is
claimed that MDMA aids patients’ ability to cope with the
distress of recollecting their trauma when required to do so in
psychotherapy (16). Similar to limbic hyperactivity, increased
coupling between the mPFC and hippocampus is a marker of
anxiety states and appears to be modulated by the 5-HT1A
receptor (53). There was a trend-level positive correlation
between the magnitude of the decreases in mPFC-
hippocampal coupling after MDMA administration and ratings
of positive mood and intensity of the drug’s global effects.
Further work is required to investigate the hypothesis that the
positive mood effects of MDMA are mediated, at least in part,
by decreased mPFC-hippocampal and mPFC-PCC coupling.
Although many aspects of the RSFC results are interesting,
we have focused on the effects that were especially marked
and are related to relevant previous work. The final effect given
special attention is the increased coupling between the
amygdala and the hippocampus after MDMA administration.
The magnitude of the increases in amygdala-hippocampal
RSFC correlated at a near significant level with ratings of therg/journal
Figure 4. Effect of 3,4-methylenedioxymetham-
phetamine (MDMA) on resting state functional con-
nectivity (RSFC). (A) Changes in ventromedial
prefrontal cortex (vmPFC) RSFC. (B) Changes in
hippocampal RSFC after MDMA administration. (C)
Changes in amygdala RSFC after MDMA administra-
tion. Increases in RSFC are shown in yellow-orange,
and decreases in RSFC are shown in blue. All seeds
are shown in red. The blue lines on the axial and
sagittal slices on the far right indicate the planar
position of the preceding slices. All images were
cluster-corrected, z 5 2.3, p , .05.
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hippocampal RSFC has been found in patients with PTSD
relative to combat veterans without PTSD (54). The authors of
the study speculated that the decrease in amygdala-
hippocampal RSFC may relate to an impaired ability to
contextualize affective information in PTSD. It is intriguing that
MDMA had an inverse effect on amygdala-hippocampal RSFC
in the present study, increasing it in a manner that correlated
with the drug’s global subjective effects (albeit at a trend level).
Further work is required test both the safety and efficacy of
MDMA in PTSD and the specific mechanisms by which it may
be effective. There is only preliminary evidence from a single
published pilot study to support the therapeutic potential of
MDMA in the treatment of PTSD (17). However, the results of
the present study indicate that the MTLs may be specifically
implicated in any potential therapeutic action of the drug.Biological PsycThere have been no previous resting state fMRI studies on
MDMA, but a steady-state positron emission tomography
study measured CBF after administration of 119 mg/70 kg
MDMA in 16 healthy volunteers (9). Because the experimental
conditions differed from the conditions of the present study
(e.g., participants performed a low-level cognitive task during
many of the scans), it is difficult to compare the study
outcomes. Some decreases in CBF were observed in the
thalamus, amygdala, and somatosensory cortex in the posi-
tron emission tomography study, but increases in CBF
(in the orbitofrontal cortex, visual cortex, and cerebellum) were
also observed. In another positron emission tomography study
of a proserotoninergic agent, intravenous fenfluramine was
administered during steady-state cognition, and increased
frontal cortical and decreased thalamic CBF was observed
(55).hiatry October 15, 2015; 78:554–562 www.sobp.org/journal 559
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MDMA human imaging study to date; however, it has some
important limitations. We did not incorporate retrospective
correction of physiological motion effects to correct for the
physiologic variance (56). However, this process had a negli-
gible effect on the results when previously applied to psilocy-
bin fMRI data (21). Similarly, the breath-hold paradigm
incorporated into the psilocybin fMRI design to test for drug-
vascular interactions did not reveal any modulatory influence
with this serotoninergic agent. Nevertheless, given the hemo-
dynamic nature of the ASL and BOLD signals, it remains
plausible that some of the observed effects were caused by a
direct vascular action of MDMA or (released) serotonin, and
the design would have benefited from the inclusion of
RETROICOR or a breath-hold paradigm, or both. However,
contradicting a direct vascular action of the drug, the observed
CBF and RSFC effects were localized to functionally mean-
ingful brain regions (e.g., the MTLs) rather than being global in
extent or proximal to regions with a high vascular input, and
the decreases in MTL CBF correlated with global subjective
effects of MDMA.
Five of the 25 participants in this study were filmed as part
of a television documentary on the effects of MDMA. These
5 participants were not filmed during scanning and completed
the study protocol in the same way as the other 20 partic-
ipants. However, to address concerns about filming being a
potential confounding variable, we reanalyzed the ASL data
after removing the five filmed participants, and the main
effects of MDMA were unchanged (Supplement 1).
A definite limitation of this study was the lack of a pharma-
cologic pretreatment component. Several pretreatment studies
with MDMA in humans have now been published (14,42,57–66),
and an advanced design would have included an antagonist
pretreatment component to elucidate the pharmacologic mech-
anism underlying the fMRI-measured effects of MDMA.
The hypothesis-driven nature of our seed-based RSFC
analyses could also be questioned. Seed-based RSFC requires
prior selection of specific seeds, and if prior hypotheses about
the functional importance of the chosen seeds are tenuous or
lacking, this selection process can seem arbitrary. However,
the selection of MTL seeds and the vmPFC in the present
study can be justified given their association with social and
affective processing (67,68) and the recognized modulatory
influence of MDMA on these functions (6,22,69). Nonetheless,
other regions of interest could have been selected if informed
by specific prior hypotheses. In contrast to seed-based RSFC,
independent components analysis is a data-driven technique
that could have been applied to the present data to identify
resting state networks, which could have been scrutinized in
between-condition analyses, either looking at between-
network RSFC between conditions or differences in RSFC
within the independent components analysis–defined net-
works. Relevant independent components analysis–based
analyses are the focus of a separate publication.
It would be misleading to infer that changes in RSFC
between a seed and other regions in the brain apply exclu-
sively to the selected seed. Indeed, the same between-
condition differences in RSFC may be shared by multiple
regions. Related to this, RSFC analyses do not provide
information on the causal source of changes in RSFC, and560 Biological Psychiatry October 15, 2015; 78:554–562 www.sobp.oto address such questions one needs to consider exploring
effective-connectivity measures (70).
Another potential limitation of the study was the inclusion of
behavioral paradigms between the first and second pair of
resting state scans. It is possible that these had carry-over
effects on the CBF and RSFC outcomes of the second pair of
scans. However, this possibility seems unlikely given that the
outcomes of the second ASL and BOLD resting state scans
were consistent with those of the first pair (Supplement 1).
Finally, the effectiveness of the blinding procedure is
compromised when studying the acute effects of a relatively
potent psychoactive drug such as MDMA. Participants cor-
rectly identified when they had received MDMA or placebo in
45 of the 50 study days, and the research team predicted
correctly in 48 of the study days. It is difficult to circumvent
this issue. A very low dose of MDMA or another stimulant such
as amphetamine could have been added as a control con-
dition. However, a drug-free baseline is required to properly
determine the effects of an experimental compound. With this
said however, the ineffectiveness of blinding needs to be
highlighted as a study limitation.
In conclusion, this is the first study to have used resting
state fMRI to address the question of how MDMA works on
the human brain to produce its characteristic subjective
effects. The results revealed decreased CBF in MTL regions,
decreased RSFC between the vmPFC and PCC, decreased
mPFC-hippocampus RSFC, and increased amygdala-
hippocampus RSFC. Taken together, the MTL regions appear
to be specifically implicated in the mechanism of action of
MDMA. However, these results should be seen as informative
rather than confirmatory, and further research is required to
elucidate the precise mechanisms by which the characteristic
subjective effects of MDMA arise from its modulation of brain
activity.
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